(CercleFinance.com) – Sanofi announces last-minute phase III data presented at the 2022 AAD (American Academy of Dermatology) Congress showing that its Dupixent (dupilumab) significantly improves the signs and symptoms of nodular prurigo.
Dupixent provided a significant reduction in itching at 12 weeks; at 24 weeks, almost three times as many patients treated with the product showed a clinically significant reduction in itching and skin lesions.
“There is currently no systemic treatment for nodular prurigo”, underlines the pharmaceutical group, which anticipates regulatory submissions in this indication in the first half of 2022.